Evidence map›Paper›PMID 38709848›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2025

Amoxicillin-Clavulanate Breakpoints Against Haemophilus influenzae: Rationale for Revision by the Clinical and Laboratory Standards Institute2.

Navaneeth Narayanan, Amy J Mathers, Eric Wenzler, Nicholas M Moore, Christian G Giske, Rodrigo E Mendes, Paul H Edelstein

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Navaneeth NarayananDepartment of Pharmacy Practice and Administration, Rutgers University Ernest Mario School of Pharmacy, Piscataway, New Jersey, USA.ORCID 0000-0001-5071-9193
Amy J MathersDepartment of Medicine and Pathology, University of Virginia, Charlottesville, Virginia, USA.ORCID 0000-0002-3533-6351
Eric WenzlerRoche Diagnostics Corporation, Indianapolis, Indiana, USA.ORCID 0000-0003-3914-8400
Nicholas M MooreDepartments of Internal Medicine and Pathology, Rush University Medical Center, Chicago, Illinois, USA.ORCID 0000-0002-9734-8905
Christian G GiskeDivision of Clinical Microbiology, Department of Laboratory Medicine, Karolinska University Hospital and Karolinska Institute, Stockholm, Sweden.ORCID 0000-0003-4327-6122
Rodrigo E MendesJMI Laboratories, North Liberty, Iowa, USA.ORCID 0000-0002-8648-1137
Paul H EdelsteinDepartment Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-4069-5279

Funding

Gut Microbiome and Pharmacokinetic Variability in Tuberculosis and DiabetesK23AI159396 · NIAID · RUTGERS, THE STATE UNIV OF N.J. · PI Navaneeth Narayanan · 2022 to 2026
$998k
AbbottAbbvie Inc.American Society for Clinical Laboratory ScienceAstellas PharmaBeckman CoulterCepheid, IncEuropean Committee on Antimicrobial Susceptibility TestingFerring PharmaceuticalsMelinta TherapeuticsMerckMerck and Shionogi IncNational Institute of Allergy and Infectious DiseasesNIAID NIH HHS K23 AI159396NIH HHS K23AI159396Qpex BiopharmaShionogi IncVenatorx Pharmaceuticals
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID38709848
PMCPMC11848255

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.